Chronic heart failure of various etiology
Код АТХ: C01AA 2
One tablet contains 200 μg alpha-acetyldigoxin.
Chronic heart failure of various etiology class II, III, IV; for reduction of ventricular response frequency in patients with atrial fibrillation and flutter.
osage and administration:
In adults, for quick saturation, the daily dose is 600 μg, divided in 3 uniform administrations for 2 days; for slow saturation the daily dose is 200-300 μg for 4 days. The daily dose for maintenance therapy is 200-300 μg. In patients with renal failure, according to createnine clearance, the dose is reduced from ј to 2/3 of the daily dose.
Digitalis intoxication; hypersensitivity to the product; hypertrophic cardiomyopathy with subaortic stenosis in sinus rhythm; aortic aneurism; acute myocardial infarction and increased ventricular excitability; high degree of sinus bradycardia; AV block II and III degree with significant bradycardia; high degree of hypokalemia; in increased ventricular excitability; frequent, polytopic, grouped and early ventricular extrasystoles and attacks of ventricular tachycardia; atrial flutter when connected with WPW-syndrome with attacks of supraventricular tachycardia; hypercalcemia.
Enhancement of negative dromo- and chronotropic effect is observed at the concomitant application with beta-blockers, antiarrhythmics, salidiuretics, laxatives, amphotericin B, glucocorticoids, ACTH products, salicylates, infusion glucose solutions. Enhancement of Lanatilin effects is possible at the concomitant application with Verapamil, Nifedipin, Diltiazem, chinidin, Amiodarone, propafenone, Captopril, spironolactone, macrolyde antibiotics (erythromycin, claritromycin) itraconazole, rifampicin. The intestinal resorption of the product is decreased at the concomitant application with: active carbon, cholestyramine, antiacids, kaolinpectin, non-steroid anti-inflammatory drugs, paraaminosalicylic acid, cytostatics, sulfasalazine, sucralfate, phenytoin, metoclopramide. M-cholinolytics delay the intestinal peristalsis and enhances the toxic effect of Lanatilin. High degree bradycardia may develop at the concomitant application with reserpine. Beta-blockers and antiarrhythmics may enhance the negative chronotropic and dromotropic effect of the product and enhance the risk of AV-block. The combination of Phenobarbitalum natricum with other enzyme products reduces its therapeutic effect. Thyreostatics enhance its effects. Heart rhythm disorders are possible at the concomitant application with sympatomimetics, cyclopropane, reserpine, tricyclic antidepressants, phosphodiesterase inhibitors, noradrenaline and dopamine. The concomitant application of calcium-containing products is not recommended during the treatment with Lanatilin.
Bradycardia, AV block, ventricular extrasystole, bigeminy, supraventricular and ventricular tachycardia; appetite inhibition, encumbrance, nausea and vomiting, diarrhea, abdominal pains; headache and drowsiness, sleep disorders, disorientation, excitement or depression, vision disorders (colour perception), hallucinations, psychoses, aphasia; hypersensitivity symptoms – erythema, rashes, thrombocytopenia; muscular pains; sexual functions disorders, gynecomastia.
50 tablets (0.2 mg).
On doctor’s prescription.
Copyright © 2016-2018 BPG Ltd/Biogenic Stimulants, Inc. All rights reserved.